The American Association of Clinical Endocrinologists published revised guidelines for treatment of diabetes on May 1, 2013. The guidelines degrade the use of glipizide and insulin. They promote the use of expensive new medications, giving them parity with metformin. This is in spite of the fact that there are few independent studies that compare new drugs to metformin or glipizide.
The members of the committee should indicate the bias they have in favor of new drugs. At least each member should reveal how much money they received from the sponsors of the new drugs.
The influence of drug companies is enormous. They fund most of the research in the academic centers. The professors cannot survive without this funding. They would lose their coveted post of professorship if they do not get funds from drug companies. The professors in turn recommend the new drugs to the practicing physicians. The new guidelines by AACE is an example of such pervasive power of the drug companies.